Healthcare >> CEO Interviews >> June 2, 2003
DR. ANDREW PERLMAN, Executive Vice President of Tularik Inc., has
been a member of Tularik's management team for nearly 10 years,
serving previously as Vice President of Medical Research and
Corporate Development. During the last decade, he played a
significant role in Tularik's evolution from a research-stage
startup to a company with multiple drugs in the clinic moving
toward commercialization. Dr. Perlman spent five years in several
senior clinical development positions at Genentech, Inc., where
he was responsible for designing, implementing and analyzing
clinical trials and filing New Drug Applications (NDAs) for U.S.
Food and Drug Administration marketing approval. He was also
responsible for Genentech's patient registry, known as the
National Cooperative Growth Study. Earlier in his career, Dr.
Perlman was a faculty member in the Department of Medicine at
Stanford University. Dr. Perlman is a member of the Board of
Directors of SangStat Medical Corporation and Cumbre Inc. He
received his MD and PhD from New York University in 1975. Profile
issue. What has gone on over the past year that investors should
focus on?
Dr. Perlman: The past year has been incredibly productive
